Center for Clinical Microbiology, Division of Infection and Immunity, University College London, NIHR Biomedical Research Centre, at UCLHospital, London, United Kingdom.
Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital Skejby, Aarhus, Denmark.
Int J Infect Dis. 2015 Mar;32:46-9. doi: 10.1016/j.ijid.2014.12.039.
Tuberculosis (TB) today remains a global emergency affecting 9.0 million people globally. The African Region bears the highest global TB/HIV burden and over 50% of TB cases in SSA are co-infected with HIV. An estimated 1.5 million died from the TB globally in 2013. A large majority of the 360,000 HIV-positive TB cases who died were from sub-Saharan Africa. Research and development is an important pillar of the WHO post-2015 global TB strategy. Advances in development of diagnostics, drugs, host-directed therapies, and vaccines will require evaluation under field conditions through multi-centre clinical trials at different geographical locations. Thus it is critically important that these evaluations are fully supported by all African governments and the capacity, trained staff and infrastructure required to perform the research and evaluations is built and made available. This viewpoint article reviews the opportunities provided by recently launched second programme (2015-2024) of the European & Developing Countries Clinical Trials Partnership (EDCTP2) for tackling the TB epidemic in Africa through its magnanimous portfolio. The unique opportunities provided by EDCTP2 for leadership of scientific research in TB and other diseases fully devolving to Africa are also covered.
结核病（TB）至今仍是影响全球 9000 万人的全球紧急情况。非洲区域承受着全球结核病/艾滋病负担最重的压力，在撒哈拉以南非洲，超过 50%的结核病病例同时感染了艾滋病毒。据估计，2013 年全球有 150 万人死于结核病。在死于结核病的 36 万例艾滋病毒阳性结核病病例中，绝大多数来自撒哈拉以南非洲。研究与开发是世卫组织 2015 年后全球结核病战略的重要支柱。诊断、药物、宿主导向疗法和疫苗的开发进展将需要在不同地理位置的多中心临床试验中在实地条件下进行评估。因此，至关重要的是，所有非洲国家政府都全力支持这些评估，并建立和提供开展研究和评估所需的能力、经过培训的工作人员和基础设施。这篇观点文章审查了欧洲和发展中国家临床试验伙伴关系（EDCTP2）最近启动的第二个方案（2015-2024 年）为通过其宏伟的投资组合来解决非洲结核病流行所提供的机会。文章还介绍了 EDCTP2 为在结核病和其他疾病方面的领导地位提供的独特机会，这些机会完全由非洲掌握。
